{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:49:37Z","timestamp":1792669777555,"version":"4.5.0"},"reference-count":41,"publisher":"American Diabetes Association","issue":"12","license":[{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"vor","delay-in-days":48,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Diabetes is the leading cause of nontraumatic lower-extremity amputations (LEAs). Identification of patients with foot ulcers at risk for amputation remains clinically challenging. Plasma copeptin, a surrogate marker of vasopressin, is associated with the risk of cardiovascular and renal complications in diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>We assessed the association between baseline plasma copeptin and risk of LEA during follow-up in four cohorts of people with type 1 (GENESIS, n = 503, and GENEDIAB, n = 207) or type 2 diabetes (DIABHYCAR, n = 3,101, and SURDIAGENE, n = 1,452) with a median duration of follow-up between 5 and 10 years. Copeptin concentration was measured in baseline plasma samples by an immunoluminometric assay.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>In the pooled cohorts with type 1 diabetes (n = 710), the cumulative incidence of LEA during follow-up by increasing tertiles (tertile 1 [TER1], TER2, and TER3) of baseline plasma copeptin was 3.9% (TER1), 3.3% (TER2), and 10.0% (TER3) (P = 0.002). Cox regression analyses confirmed the association of copeptin with LEA: hazard ratio (HR) for 1 SD increment of log[copeptin] was 1.89 (95% CI 1.28\u20132.82), P = 0.002. In the pooled cohorts of type 2 diabetes (n = 4,553), the cumulative incidence of LEA was 1.1% (TER1), 2.9% (TER2), and 3.6% (TER3) (P &amp;lt; 0.0001). In Cox regression analyses, baseline plasma copeptin was significantly associated with LEA: HR for 1 SD increment of log[copeptin] was 1.42 (1.15\u20131.74), P = 0.001. Similar results were observed in the cohort with type 2 diabetes for lower-limb revascularization (HR 1.20 [95% CI 1.03\u20131.39], P = 0.02).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Baseline plasma copeptin is associated with cumulative incidence of LEA in cohorts of people with both type 1 and type 2 diabetes and may help to identify patients at risk for LEA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc19-1062","type":"journal-article","created":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T22:05:18Z","timestamp":1570140318000},"page":"2290-2297","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":23,"title":["Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes"],"prefix":"10.2337","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6268-7360","authenticated-orcid":false,"given":"Louis","family":"Potier","sequence":"first","affiliation":[{"name":"Department of Diabetology, Endocrinology and Nutrition, DHU FIRE, Bichat Hospital, Assistance Publique \u2013 H\u00f4pitaux de Paris, Paris, France"},{"name":"Universit\u00e9 de Paris, Paris, France"},{"name":"INSERM, UMRS 1138, Cordeliers Research Center, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2292-8363","authenticated-orcid":false,"given":"Ronan","family":"Roussel","sequence":"additional","affiliation":[{"name":"Department of Diabetology, Endocrinology and Nutrition, DHU FIRE, Bichat Hospital, Assistance Publique \u2013 H\u00f4pitaux de Paris, Paris, France"},{"name":"Universit\u00e9 de Paris, Paris, France"},{"name":"INSERM, UMRS 1138, Cordeliers Research Center, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3071-1837","authenticated-orcid":false,"given":"Michel","family":"Marre","sequence":"additional","affiliation":[{"name":"Department of Diabetology, Endocrinology and Nutrition, DHU FIRE, Bichat Hospital, Assistance Publique \u2013 H\u00f4pitaux de Paris, Paris, France"},{"name":"Universit\u00e9 de Paris, Paris, France"},{"name":"INSERM, UMRS 1138, Cordeliers Research Center, Paris, France"},{"name":"Section of Endocrinology, Department of Pediatrics, and Division of Nephrology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5160-2947","authenticated-orcid":false,"given":"Petter","family":"Bjornstad","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Department of Pediatrics, and Division of Nephrology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z.","family":"Cherney","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"El Boustany","sequence":"additional","affiliation":[{"name":"Department of Diabetology, Endocrinology and Nutrition, DHU FIRE, Bichat Hospital, Assistance Publique \u2013 H\u00f4pitaux de Paris, Paris, France"},{"name":"INSERM, UMRS 1138, Cordeliers Research Center, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Fumeron","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Paris, France"},{"name":"INSERM, UMRS 1138, Cordeliers Research Center, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Venteclef","sequence":"additional","affiliation":[{"name":"INSERM, UMRS 1138, Cordeliers Research Center, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6458-2001","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Gautier","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Paris, France"},{"name":"INSERM, UMRS 1138, Cordeliers Research Center, Paris, France"},{"name":"Department of Diabetes, Clinical Investigation Centre (CIC-9504), Lariboisi\u00e8re Hospital, Assistance Publique \u2013 H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7110-6994","authenticated-orcid":false,"given":"Samy","family":"Hadjadj","sequence":"additional","affiliation":[{"name":"L\u2019Institut du thorax, INSERM, CNRS, Universit\u00e9 de Nantes, Centre Hospitalier Universitaire de Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6139-1197","authenticated-orcid":false,"given":"Kamel","family":"Mohammedi","sequence":"additional","affiliation":[{"name":"Department of Diabetology, Endocrinology and Nutrition, H\u00f4pital Haut-L\u00e9v\u00eaque, Bordeaux, France"},{"name":"Bordeaux University, Bordeaux, France"},{"name":"INSERM U1219 \u201cBordeaux Population Health,\u201d Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Velho","sequence":"additional","affiliation":[{"name":"INSERM, UMRS 1138, Cordeliers Research Center, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2019,10,3]]},"reference":[{"key":"2022031300532668700_B1","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.2337\/dc15-0536","article-title":"Diabetes, lower-extremity amputation, and death","volume":"38","author":"Hoffstad","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031300532668700_B2","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1056\/NEJMra1615439","article-title":"Diabetic foot ulcers and their recurrence","volume":"376","author":"Armstrong","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031300532668700_B3","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00125-019-4835-z","article-title":"Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use","volume":"62","author":"Potier","year":"2019","journal-title":"Diabetologia"},{"key":"2022031300532668700_B4","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1681\/ASN.2010070691","article-title":"Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus","volume":"22","author":"Fenske","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2022031300532668700_B5","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.2337\/dc13-0683","article-title":"Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria","volume":"36","author":"Velho","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031300532668700_B6","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1007\/s00125-013-2922-0","article-title":"Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33)","volume":"56","author":"Boertien","year":"2013","journal-title":"Diabetologia"},{"key":"2022031300532668700_B7","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1007\/s00125-016-4011-7","article-title":"Copeptin and the risk of incident stroke, CHD and cardiovascular mortality in older men with and without diabetes: the British Regional Heart Study","volume":"59","author":"Wannamethee","year":"2016","journal-title":"Diabetologia"},{"key":"2022031300532668700_B8","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.2337\/dc16-1003","article-title":"Plasma copeptin, kidney outcomes, ischemic heart disease, and all-cause mortality in people with long-standing type 1 diabetes","volume":"39","author":"Velho","year":"2016","journal-title":"Diabetes Care"},{"key":"2022031300532668700_B9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12933-018-0753-5","article-title":"Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes","volume":"17","author":"Velho","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"2022031300532668700_B10","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1172\/JCI119321","article-title":"Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group","volume":"99","author":"Marre","year":"1997","journal-title":"J Clin Invest"},{"key":"2022031300532668700_B11","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.2337\/diacare.27.11.2661","article-title":"Different patterns of insulin resistance in relatives of type 1 diabetic patients with retinopathy or nephropathy: the Genesis France-Belgium Study","volume":"27","author":"Hadjadj","year":"2004","journal-title":"Diabetes Care"},{"key":"2022031300532668700_B12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/bmj.37970.629537.0D","article-title":"Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study)","volume":"328","author":"Marre","year":"2004","journal-title":"BMJ"},{"key":"2022031300532668700_B13","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.2337\/dc07-2079","article-title":"Prognostic value of the insertion\/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) studies","volume":"31","author":"Hadjadj","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031300532668700_B14","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2022031300532668700_B15","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1373\/clinchem.2005.060038","article-title":"Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin","volume":"52","author":"Morgenthaler","year":"2006","journal-title":"Clin Chem"},{"key":"2022031300532668700_B16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/biostatistics\/2.1.85","article-title":"Regression modeling of competing crude failure probabilities","volume":"2","author":"Fine","year":"2001","journal-title":"Biostatistics"},{"key":"2022031300532668700_B17","doi-asserted-by":"crossref","first-page":"e121479","DOI":"10.1172\/jci.insight.121479","article-title":"Plasma copeptin and chronic kidney disease risk in 3 European cohorts from the general population","volume":"3","author":"El Boustany","year":"2018","journal-title":"JCI Insight"},{"key":"2022031300532668700_B18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrneph.2013.22","article-title":"Vasopressin: a novel target for the prevention and retardation of kidney disease","volume":"9","author":"Bankir","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"2022031300532668700_B19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2337\/diacare.23.2.215","article-title":"Impaired skin microvascular function in children, adolescents, and young adults with type 1 diabetes","volume":"23","author":"Khan","year":"2000","journal-title":"Diabetes Care"},{"key":"2022031300532668700_B20","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1177\/1479164114544464","article-title":"Plasma copeptin as marker of cardiovascular disease in asymptomatic type 2 diabetes patients","volume":"11","author":"Bar-Shalom","year":"2014","journal-title":"Diab Vasc Dis Res"},{"key":"2022031300532668700_B21","doi-asserted-by":"crossref","first-page":"351","DOI":"10.5551\/jat.44891","article-title":"Inflammatory mediators across the spectrum of ankle-brachial index","volume":"26","author":"Ozkaramanli Gur","year":"2019","journal-title":"J Atheroscler Thromb"},{"key":"2022031300532668700_B22","doi-asserted-by":"crossref","first-page":"H1661","DOI":"10.1152\/ajpheart.00432.2009","article-title":"Vasopressin is a major vasoconstrictor involved in hindlimb vascular responses to stimulation of adenosine A(1) receptors in the nucleus of the solitary tract","volume":"297","author":"McClure","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2022031300532668700_B23","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.brainres.2016.02.038","article-title":"Rapidly increased vasopressin promotes acute platelet aggregation and early brain injury after experimental subarachnoid hemorrhage in a rat model","volume":"1639","author":"Liu","year":"2016","journal-title":"Brain Res"},{"key":"2022031300532668700_B24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1172\/JCI9516","article-title":"Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP","volume":"106","author":"Kaufmann","year":"2000","journal-title":"J Clin Invest"},{"key":"2022031300532668700_B25","doi-asserted-by":"crossref","first-page":"F931","DOI":"10.1152\/ajprenal.00604.2013","article-title":"The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors","volume":"306","author":"Juul","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022031300532668700_B26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000439061","article-title":"Plasma copeptin and decline in renal function in a cohort from the community: the prospective D.E.S.I.R. study","volume":"42","author":"Roussel","year":"2015","journal-title":"Am J Nephrol"},{"key":"2022031300532668700_B27","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jdiacomp.2017.04.005","article-title":"Antagonism of vasopressin V2 receptor improves albuminuria at the early stage of diabetic nephropathy in a mouse model of type 2 diabetes","volume":"31","author":"El Boustany","year":"2017","journal-title":"J Diabetes Complications"},{"key":"2022031300532668700_B28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/MNH.0000000000000335","article-title":"Vasopressin and diabetic nephropathy","volume":"26","author":"Roussel","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2022031300532668700_B29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"2022031300532668700_B30","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S2213-8587(17)30183-3","article-title":"Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data","volume":"5","author":"Matsushita","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031300532668700_B31","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/joim.12645","article-title":"Vasopressin: physiology, assessment and osmosensation","volume":"282","author":"Bankir","year":"2017","journal-title":"J Intern Med"},{"key":"2022031300532668700_B32","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1210\/jc.2007-0232","article-title":"Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects","volume":"92","author":"Szinnai","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031300532668700_B33","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/jama.1974.03230490039020","article-title":"Diuretic agents: inciting factor in nonocclusive mesenteric infarction","volume":"229","author":"Sharefkin","year":"1974","journal-title":"JAMA"},{"key":"2022031300532668700_B34","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/bmj.1.6120.1114","article-title":"Reversible leg ischaemia due to diuretics","volume":"1","author":"O\u2019Rourke","year":"1978","journal-title":"BMJ"},{"key":"2022031300532668700_B35","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031300532668700_B36","doi-asserted-by":"crossref","first-page":"k4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"key":"2022031300532668700_B37","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamainternmed.2018.3034","article-title":"Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes","volume":"178","author":"Chang","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2022031300532668700_B38","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2022031300532668700_B39","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.diabres.2018.03.027","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - a systematic review","volume":"140","author":"R\u00e5dholm","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031300532668700_B40","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1210\/jc.2014-2295","article-title":"Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease","volume":"99","author":"Roussel","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031300532668700_B41","doi-asserted-by":"crossref","first-page":"e008634","DOI":"10.1136\/bmjopen-2015-008634","article-title":"Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial","volume":"5","author":"Sontrop","year":"2015","journal-title":"BMJ Open"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/42\/12\/2290\/528758\/dc191062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/42\/12\/2290\/528758\/dc191062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T04:23:56Z","timestamp":1647145436000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/42\/12\/2290\/36254\/Plasma-Copeptin-and-Risk-of-Lower-Extremity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,3]]},"references-count":41,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,10,3]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc19-1062","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,3]]}}}